Loading company…
Seoul developer of multiplex in vitro diagnostics using its SG Cap technology for infectious disease and COVID-19 testing.
Founded in 2008 and headquartered in Seoul, South Korea, PCL, Inc. develops multiplex in vitro diagnostics, including multi-immune diagnostics on its SG Cap technology, which detects several biomarkers at once. Its products cover mass screening for infectious diseases, point-of-care testing and COVID-19 solutions, sold to healthcare providers, laboratories and research institutions. The company raised KRW 12 billion through a PIPE investment in February 2017. Its CEO is Soyoun Kim.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in